Skip to main content

Table 1 Baseline characteristics of the study population

From: Pharmacometabolomic profiles in type 2 diabetic subjects treated with liraglutide or glimepiride

 

Liraglutide n  = 33

Glimepiride n  =  29

p value

Age, years

60.8 (7.6)

63.0 (6.8)

0.240a

Male sex

24 (72.7)

21 (72.4)

1.000b

Diabetes duration, years

5 (1, 10)

1 (3, 7)

0.368c

Smoking

3 (9.1)

4 (13.8)

0.852b

BMI, kg/m2

30.5 (4.4)

29.0 (3.2)

0.152a

Body weight, kg

91.8 (15.9)

89.0 (9.9)

0.411a

Waist circumference, cm

109.0 (13.0)

106.3 (9.7)

0.366a

Mean systolic BP, mmHg

131.9 (14.0)

129.3 (10.9)

0.414a

Mean diastolic BP, mmHg

76.7 (7.9)

77.2 (7.9)

0.838a

eGFR, mL/min/1.72 m2

88.3 (15.0)

87.4 (13.1)

0.799a

Complications

 Hypertension

29 (87.9)

21 (72.4)

0.224b

 Hyperlipidemia

25 (75.8)

23 (79.3)

0.980b

 Myocardial infarction

10 (30.3)

11 (37.9)

0.714b

 Stroke

1 (3)

2 (6.9)

0.902b

 Proliferative retinopathy

1 (3)

1 (3.4)

1.000b

Treatment

 Antiplatelet therapy

11 (33.3)

12 (41.4)

0.696b

 Anticoagulant treatment

3 (9.1)

1 (3.4)

0.714b

 ACE inhibitors/ARB blockers

25 (75.8)

20 (69)

0.754b

 Beta-blockers

14 (42.4)

13 (44.8)

1.000b

 Calcium inhibitors

13 (39.4)

10 (34.5)

0.894b

 Diuretics

11 (33.3)

6 (20.7)

0.408b

 Statins

22 (66.7)

24 (82.8)

0.248b

Biochemical parameters

 HbA1c, mmol/mol

54 (50, 60)

50 (49, 54)

0.036c

 Triglycerides, mmol/L

2.0 (1.4, 2.6)

1.5 (1.0, 2.2)

0.029c

 Total cholesterol, mmol/L

4.4 (4.0, 6.0)

4.5 (3.7, 4.8)

0.370c

 LDL-cholesterol, mmol/L

2.8 (1.2)

2.5 (1.0)

0.440a

 HDL-cholesterol, mmol/L

1.1 (0.3)

1.2 (0.3)

0.417a

  1. Quantitative data are mean (SD) or median (1st quartile, 3rd quartile), and categorical data are n (%)
  2. ARB angiotensin receptor blockers; BP blood pressure; eGFR estimated glomerular filtration rate; HbA1c glycated hemoglobin A1c
  3. aStudent’s t test was used
  4. bDoubled one-sided p value from Fisher’s exact test
  5. cMann–Whitney U test was used